Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07468292

GARDE : GC7 (N1-guanyl-1,7 Diaminoheptane) cARDiac arrEst

Impact of GC7 (N1-guanyl-1,7 Diaminoheptane) on Oxidative Stress in Patients Who Have Experienced a Resuscitated Cardiorespiratory Arrest

Status
Not Yet Recruiting
Phase
N/A
Study type
Interventional
Enrollment
20 (estimated)
Sponsor
Centre Hospitalier Universitaire de Nice · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Cardiac arrest (CA) with return of spontaneous circulation is associated with high mortality, exceeding 90% in out-of-hospital settings and approaching 50% in in-hospital settings. Despite management of the underlying cause of CA, patients often die from post-anoxic brain injury or from ischemia-reperfusion injury occurring after reperfusion and reoxygenation, which increases oxidative stress and leads to multi-organ failure. To date, no effective therapeutic strategy has been established in humans to limit these ischemia-reperfusion injuries. GC7 (N1-guanyl-1,7 diaminoheptane) has demonstrated a strong protective potential against ischemia reperfusion injury in rodent and porcine models, including myocardial infarction, stroke, and renal transplantation. These protective effects are attributed to the pleiotropic action of GC7 which renders cells and tissues energetically less dependent on oxygen, and reduces oxidative stress which play a major role in ischemia reperfusion injury. Degree of blood acidification and immune dysregulation may also represent parameters that GC7 could potentially influence. Although no adverse effects have been reported in these experimental models, GC7 has not yet been studied in human. Our study therefore aims to demonstrate the protective effect of GC7 on blood cells in patients after CA by evaluating oxidative stress levels, blood acidification and inflammatory profile.

Conditions

Interventions

TypeNameDescription
OTHERGC7 exposure24-hour exposure of patient 's blood to GC7 molecule
OTHERNo GC7 exposureNo exposure of blood to GC7 molecule

Timeline

Start date
2026-07-01
Primary completion
2028-07-01
Completion
2028-12-01
First posted
2026-03-12
Last updated
2026-03-16

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT07468292. Inclusion in this directory is not an endorsement.